U.S. Consumer Durables Stock News

RTX (RTX) opened the new year with Q1 2026 results coming on the heels of Q4 2025 revenue of US$24.2b and basic EPS of US$1.21, supported by Q4 net income of US$1.6b. Over the last six reported quarters, revenue moved from US$21.6b in Q4 2024 to US$24.2b in Q4 2025, while quarterly basic EPS ranged from US$1.10 to US$1.43. This sets up trailing twelve month EPS of US$5.02 and net income of US$6.7b as the reference point for today’s update, so the focus now is on how Q1 margins held up against...

With no single headline event setting the tone, Flowserve (FLS) is drawing interest as investors weigh its recent share performance, current valuation metrics, and the scale of its industrial flow management business. See our latest analysis for Flowserve. The share price has pulled back 1.6% over the last day to US$82.04, but a 14.9% 1 month share price return sits alongside a 99.7% 1 year total shareholder return, which suggests momentum has been strong over both shorter and longer...

Halliburton (HAL) has just opened its books on the latest period, with trailing 12 month revenue most recently sitting at about US$22.2b and basic EPS shifting from US$2.84 a year ago to US$1.50 on the most recent trailing view, setting a very different earnings backdrop for investors to interpret. Over the last reported quarters, quarterly revenue has moved between US$5,417m and US$5,697m while basic EPS has ranged from US$0.02 to around US$0.70, giving a wide spread of earnings outcomes...

On March 30, 2026, Butterfly Network announced it had secured FDA approval for its AI-powered handheld ultrasound tool that estimates gestational age to support clinicians in emergency and rural settings. This clearance highlights Butterfly’s effort to pair portable imaging hardware with embedded AI, aiming to broaden access to maternal care in underserved communities. We’ll now examine how FDA clearance of Butterfly’s gestational-age AI tool may influence its investment narrative and...

If you are wondering whether Micron Technology's current share price lines up with its underlying value, this breakdown will help you connect the recent moves in the stock with what you are actually paying for. The stock last closed at US$449.38, with returns of 6.3% over the past 30 days, a 42.5% gain year to date, and a very large return over the past year that is above 500%. Recent headlines have focused on Micron as a key name in the semiconductor space, with investors closely watching...

Why Eaton Stock Is Back in Focus After Its Data Center Move Eaton (ETN) has come back on many investors’ radar after formally creating a dedicated Data Center segment, following its US$9.5b Boyd thermal acquisition, to focus on integrated power and liquid cooling for AI data centers. See our latest analysis for Eaton. These data center announcements have come alongside a strong run in the stock, with a 30 day share price return of 14.8% and a 1 year total shareholder return of 55.4%. This...

Home Bancorp (HBCP) opened Q1 2026 reporting context around a trailing twelve month revenue base of about US$148.7 million and Basic EPS of US$5.93, backed by Q4 2025 net income of US$11.41 million on revenue of US$37.7 million. Over recent quarters, revenue has moved from US$34.1 million in Q4 2024 to US$37.7 million in Q4 2025, while quarterly Basic EPS has shifted from US$1.22 to US$1.48, supported by a net profit margin that sits at 31% versus 27.5% a year earlier and earnings growth of...

Flexsteel Industries (FLXS) has just posted its latest numbers, with recent quarterly revenue at about US$118.2 million and basic EPS of roughly US$1.24, set against trailing 12 month revenue of US$457.3 million and EPS of US$3.95 that also reflect a one off loss of US$9.6 million in the period. Over recent quarters, revenue has moved from US$104.0 million in early 2025 to US$118.2 million in the latest reported quarter. Quarterly EPS has ranged from US$0.80 to US$2.03 across that stretch,...

Mercantile Bank (MBWM) just posted another quarter of steady profitability, with Q4 2025 revenue at US$61.8 million and net income of US$22.8 million, which translates into basic EPS of US$1.40 ahead of its Q1 2026 reporting period. Over recent quarters the bank has seen revenue move from US$56.3 million in Q4 2024 to US$61.8 million in Q4 2025, while basic EPS increased from US$1.22 to US$1.40, giving investors a clear picture of consistent earnings power heading into the new year. With...

NETSTREIT (NTST) has kicked off its Q1 2026 reporting cycle with investors looking back at a steady run of quarterly numbers, including Q4 2025 revenue of US$52.7 million and basic EPS of US$0.02, supported by the REIT focused measure of Funds From Operations of US$26.6 million. Over the past year, the company has seen revenue move from US$44.1 million in Q4 2024 to US$52.7 million in Q4 2025, while basic EPS shifted from a loss of US$0.07 to a modest profit of US$0.02. This sets the backdrop...

Vicor (VICR) has reported a strong set of numbers heading into its Q1 2026 update, with Q4 2025 revenue of US$107.3 million, basic EPS of US$1.03 and trailing 12 month net income of US$118.6 million on revenue of US$407.7 million. This was accompanied by very strong year over year earnings growth that includes a one off gain of US$37.5 million. Over the last few quarters, revenue has moved from US$93.2 million in Q3 2024 to US$96.2 million in Q4 2024 and then to US$107.3 million in Q4 2025...

AbCellera Biologics recently announced that it will share interim Phase 1 data for ABCL635, its potential first-in-class non-hormonal antibody targeting the neurokinin 3 receptor for menopausal vasomotor symptoms, during its first-quarter 2026 earnings call on May 11, 2026. This update marks the first clinical readout from AbCellera’s GPCR and ion channel platform, highlighting how its transition into a clinical-stage pipeline is beginning to be tested in humans. We’ll now examine how the...

POET Technologies recently addressed a short report about U.S. tax complications linked to its passive foreign investment company status and outlined plans, including a potential U.S. headquarters move, to ease the burden on American shareholders. At the same time, the company reported audited Q4 2025 results showing a shift from development to execution, supported by over US$375.00 million of fresh financing and growing commercialization of its optical solutions for AI and hyperscale data...

In April 2026, Zymeworks Inc. presented six sets of new preclinical data at the AACR Annual Meeting, highlighting progress across its antibody-drug conjugate and novel payload programs targeting RAS-mutant and other hard-to-treat cancers. The breadth of first-in-class ADC constructs and new payload classes, including pan-RAS and mRNA translation inhibitors, underscores Zymeworks’ ambition to build a differentiated oncology technology stack rather than rely on a single lead asset. We’ll now...

Parker-Hannifin recently reported its third-quarter results, with Wall Street having expected diluted EPS of $7.81, an increase of 12.5% from $6.94 a year earlier. Investor attention is heightened because the company has outpaced consensus EPS forecasts in each of the previous four quarters, raising interest in whether that pattern can continue. Next, we will examine how expectations for double-digit EPS growth this quarter affect Parker-Hannifin’s broader investment narrative and long-term...

Recent performance snapshot American Electric Power Company (AEP) has drawn fresh attention after recent share price moves, with the stock showing a month return of 6.1% and a past 3 months return of 11.8%. Over longer periods, total returns stand at 15.1% year to date, 30.5% over the past year, 58.3% over three years, and 82.5% over five years, all in US$ terms. See our latest analysis for American Electric Power Company. With the latest share price at US$133.28 and a 30 day share price...

Recent performance snapshot Acadia Healthcare Company (ACHC) has drawn attention after a recent share price move, with the stock closing at $27.84 and posting gains over the past week, month and past 3 months. See our latest analysis for Acadia Healthcare Company. The recent 1 day share price return of 3.11% sits within a strong run, with a 30 day share price return of 22.48% and a 90 day share price return of 95.51%. However, the 3 year total shareholder return of negative 62.31% shows that...

What Toll Brothers’ recent returns tell you Toll Brothers (TOL) has drawn attention after an 11.6% move over the past month, adding to a 61.1% total return over the past year and 151.3% over five years. With a market value of about US$13.9b, Toll Brothers generates US$11.3b in revenue and US$1.4b in net income. This positions it as a large US luxury homebuilder with nationwide exposure across several regional segments. See our latest analysis for Toll Brothers. That recent 11.6% 1 month share...

In April 2026, Prologis reported first-quarter 2026 results showing sales of US$2,125.08 million, revenue of US$2,297.72 million, and net income of US$981.98 million, while also raising its full-year 2026 net earnings guidance range for common stockholders to US$3.80–US$4.05 per share. Alongside these results, Prologis deepened its global logistics footprint through the planned Prologis Logistics Investment Venture Europe with La Caisse and highlighted growing data center ambitions with new...

Axsome Therapeutics recently attracted attention after Oppenheimer highlighted an “attractive setup” around the now-past US FDA priority review decision on expanding Auvelity’s label to include Alzheimer’s disease agitation. The broker emphasized Auvelity’s differentiated safety profile and potential for longer-term use, arguing these features could support advantageous formulary positioning versus competing treatments. Next, we’ll examine how expectations around the Alzheimer’s agitation...

Fidelis Insurance Holdings Ltd. recently completed the early redemption of its 6.625% Fixed-Rate Junior Notes due April 1, 2041, leading to their de-listing from the Bermuda Stock Exchange effective April 8, 2026, under Regulation 6.17 (3). This early redemption highlights an active reshaping of Fidelis’s capital structure, which may influence how investors assess its balance sheet flexibility and funding mix. We’ll now examine how Fidelis’s early redemption and de-listing of junior notes...

In April 2026, Proto Labs launched ProDesk by Protolabs, an upgraded e-commerce platform that offers real-time AI-powered quoting, design-for-manufacturability analysis, and collaboration tools aimed at accelerating aerospace product development from prototyping through production. This move highlights Proto Labs’ push to embed AI deeper into its digital manufacturing workflow, potentially making it a more integral partner for aerospace and other complex, regulated industries. Next, we’ll...

Alpha and Omega Semiconductor recently celebrated the inauguration of Kaynes Semicon’s OSAT facility in Sanand, Gujarat, where its proprietary IPM5 manufacturing process is now in high-volume production for global power semiconductor customers. By bringing advanced packaging and testing capabilities online in just 14 months, the collaboration deepens Alpha and Omega Semiconductor’s manufacturing presence in India while supporting the India Semiconductor Mission’s goal of building...

Recent commentary on MYR Group highlights concern that its sales pipeline and average backlog growth of 5.4% over the past two years may not support earlier revenue growth expectations. With a forward P/E ratio of 34.2x, MYR Group’s weaker gross margin of 10.8% and waning returns on capital are drawing attention to potential profitability pressure. Next, we’ll examine how concerns about MYR Group’s slower backlog growth may reshape its previously measured, contract-driven investment...